Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

MLA

Golshan, Mehra, et al. “Impact of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-Conserving Surgery and Breast Conservation Rates: Surgical Results from CALGB 40603 (Alliance).” Annals of Surgery, vol. 262, no. 3, Sept. 2015, pp. 434–39. EBSCOhost, https://doi.org/10.1097/SLA.0000000000001417.

APA

Golshan, M., Cirrincione, C. T., Sikov, W. M., Berry, D. A., Jasinski, S., Weisberg, T. F., Somlo, G., Hudis, C., Winer, E., & Ollila, D. W. (2015). Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Annals of Surgery, 262(3), 434–439. https://doi.org/10.1097/SLA.0000000000001417

Chicago

Golshan, Mehra, Constance T Cirrincione, William M Sikov, Donald A Berry, Sara Jasinski, Tracey F Weisberg, George Somlo, Clifford Hudis, Eric Winer, and David W Ollila. 2015. “Impact of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-Conserving Surgery and Breast Conservation Rates: Surgical Results from CALGB 40603 (Alliance).” Annals of Surgery 262 (3): 434–39. doi:10.1097/SLA.0000000000001417.